Jason S Mclellan

List of Publications by Year
in descending order

114 papers	27,244 citations	31902 53 h-index	22764 112 g-index
157 all docs	157 docs citations	157 times ranked	30075 citing authors

#	Article	IF	Citations
1	Glycosylation and Serological Reactivity of an Expression-enhanced SARS-CoV-2 Viral Spike Mimetic. Journal of Molecular Biology, 2022, 434, 167332.	2.0	22
2	Structural basis of synergistic neutralization of Crimean-Congo hemorrhagic fever virus by human antibodies. Science, 2022, 375, 104-109.	6.0	15
3	Structural basis for HCMV Pentamer recognition by neuropilin 2 and neutralizing antibodies. Science Advances, 2022, 8, eabm2546.	4.7	8
4	Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial. EClinicalMedicine, 2022, 45, 101323.	3.2	26
5	The SARS-CoV-2 spike reversibly samples an open-trimer conformation exposing novel epitopes. Nature Structural and Molecular Biology, 2022, 29, 229-238.	3.6	81
6	Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking. Nature Biotechnology, 2022, 40, 1270-1275.	9.4	27
7	Structure-based design of prefusion-stabilized human metapneumovirus fusion proteins. Nature Communications, 2022, 13, 1299.	5.8	26
8	Analysis of Viral Spike Protein N-Glycosylation Using Ultraviolet Photodissociation Mass Spectrometry. Analytical Chemistry, 2022, 94, 5776-5784.	3.2	10
9	Protein engineering responses to the COVID-19 pandemic. Current Opinion in Structural Biology, 2022, 74, 102385.	2.6	11
10	Cryo-EM structure of the EBV ribonucleotide reductase BORF2 and mechanism of APOBEC3B inhibition. Science Advances, 2022, 8, eabm2827.	4.7	15
11	Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam. Vaccine, 2022, 40, 3621-3632.	1.7	15
12	Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice. Npj Vaccines, 2022, 7, .	2.9	32
13	Principles and practical applications of structure-based vaccine design. Current Opinion in Immunology, 2022, 77, 102209.	2.4	17
14	Structural basis for ultrapotent antibody-mediated neutralization of human metapneumovirus. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	8
15	Elicitation of pneumovirus-specific B cell responses by a prefusion-stabilized respiratory syncytial virus F subunit vaccine. Science Translational Medicine, 2022, 14, .	5.8	7
16	Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants. Clinical Infectious Diseases, 2021, 73, e4400-e4408.	2.9	77
17	Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape. Nature Communications, 2021, 12, 469.	5.8	148
18	Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. Science, 2021, 371, 823-829.	6.0	285

#	Article	IF	Citations
19	Prolonged evolution of the human B cell response to SARS-CoV-2 infection. Science Immunology, 2021, 6, .	5.6	153
20	Local computational methods to improve the interpretability and analysis of cryo-EM maps. Nature Communications, 2021, 12, 1240.	5.8	36
21	Prefusion Fâ€"Based Polyanhydride Nanovaccine Induces Both Humoral and Cell-Mediated Immunity Resulting in Long-Lasting Protection against Respiratory Syncytial Virus. Journal of Immunology, 2021, 206, 2122-2134.	0.4	6
22	Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. Nature, 2021, 594, 253-258.	13.7	253
23	The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Science Translational Medicine, 2021, 13, .	5.8	347
24	Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses. Immunity, 2021, 54, 769-780.e6.	6.6	37
25	A Vulnerable, Membrane-Proximal Site in Human Respiratory Syncytial Virus F Revealed by a Prefusion-Specific Single-Domain Antibody. Journal of Virology, 2021, 95, .	1.5	8
26	Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes. Science, 2021, 372, 1108-1112.	6.0	210
27	Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. Cell Reports Medicine, 2021, 2, 100313.	3.3	56
28	Protective neutralizing antibodies from human survivors of Crimean-Congo hemorrhagic fever. Cell, 2021, 184, 3486-3501.e21.	13.5	39
29	A glycan gate controls opening of the SARS-CoV-2 spike protein. Nature Chemistry, 2021, 13, 963-968.	6.6	254
30	SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	251
31	Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition. Cell Reports, 2021, 37, 109784.	2.9	20
32	Early cross-coronavirus reactive signatures of humoral immunity against COVID-19. Science Immunology, 2021, 6, eabj2901.	5.6	67
33	Structural basis for antibody binding to adenylate cyclase toxin reveals RTX linkers as neutralization-sensitive epitopes. PLoS Pathogens, 2021, 17, e1009920.	2.1	9
34	Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants. Nature Communications, 2021, 12, 5652.	5.8	49
35	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. Cell, 2021, 184, 5432-5447.e16.	13.5	131
36	A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants. MBio, 2021, 12, e0247321.	1.8	35

#	Article	IF	Citations
37	Expression and characterization of SARS-CoV-2 spike proteins. Nature Protocols, 2021, 16, 5339-5356.	5.5	31
38	Stabilized coronavirus spike stem elicits a broadly protective antibody. Cell Reports, 2021, 37, 109929.	2.9	64
39	Structural basis of synergistic neutralization of Crimean-Congo hemorrhagic fever virus by human antibodies. Science, 2021, , eabl6502.	6.0	2
40	SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature, 2020, 586, 567-571.	13.7	1,153
41	Trimeric SARS-CoV-2 Spike Proteins Produced from CHO Cells in Bioreactors Are High-Quality Antigens. Processes, 2020, 8, 1539.	1.3	18
42	Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science, 2020, 369, 1501-1505.	6.0	977
43	Recognition of a highly conserved glycoprotein B epitope by a bivalent antibody neutralizing HCMV at a post-attachment step. PLoS Pathogens, 2020, 16, e1008736.	2.1	17
44	Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area. MBio, 2020, 11, .	1.8	99
45	Beyond Shielding: The Roles of Glycans in the SARS-CoV-2 Spike Protein. ACS Central Science, 2020, 6, 1722-1734.	5.3	727
46	Site-specific glycan analysis of the SARS-CoV-2 spike. Science, 2020, 369, 330-333.	6.0	1,277
47	Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies. Cell, 2020, 181, 1004-1015.e15.	13.5	506
48	Structure and Characterization of Crimean-Congo Hemorrhagic Fever Virus GP38. Journal of Virology, 2020, 94, .	1.5	28
49	Immunogenicity of a DNA vaccine candidate for COVID-19. Nature Communications, 2020, 11, 2601.	5.8	514
50	Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein ofÂMiddle East respiratory syndrome coronavirus. PLoS ONE, 2020, 15, e0232757.	1.1	11
51	Vulnerabilities in coronavirus glycan shields despite extensive glycosylation. Nature Communications, 2020, 11, 2688.	5.8	304
52	Structure-Based Design of Nipah Virus Vaccines: A Generalizable Approach to Paramyxovirus Immunogen Development. Frontiers in Immunology, 2020, 11, 842.	2.2	36
53	Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science, 2020, 369, 731-736.	6.0	534
54	Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization. Journal of Virology, 2020, 94, .	1.5	37

#	Article	IF	Citations
55	Structure-Based Design of Prefusion-Stabilized Filovirus Glycoprotein Trimers. Cell Reports, 2020, 30, 4540-4550.e3.	2.9	46
56	Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science, 2020, 367, 1260-1263.	6.0	7,517
57	Continuous flexibility analysis of SARS-CoV-2 spike prefusion structures. IUCrJ, 2020, 7, 1059-1069.	1.0	39
58	Title is missing!. , 2020, 16, e1008736.		0
59	Title is missing!. , 2020, 16, e1008736.		0
60	Title is missing!. , 2020, 16, e1008736.		0
61	Title is missing!. , 2020, 16, e1008736.		0
62	A proof of concept for structure-based vaccine design targeting RSV in humans. Science, 2019, 365, 505-509.	6.0	207
63	Alternative conformations of a major antigenic site on RSV F. PLoS Pathogens, 2019, 15, e1007944.	2.1	29
64	Structural Definition of a Neutralization-Sensitive Epitope on the MERS-CoV S1-NTD. Cell Reports, 2019, 28, 3395-3405.e6.	2.9	63
65	Structure-Based Vaccine Antigen Design. Annual Review of Medicine, 2019, 70, 91-104.	5.0	160
66	Respiratory syncytial virus entry and how to block it. Nature Reviews Microbiology, 2019, 17, 233-245.	13.6	187
67	Transient opening of trimeric prefusion RSV F proteins. Nature Communications, 2019, 10, 2105.	5.8	71
68	The 3.1-Angstrom Cryo-electron Microscopy Structure of the Porcine Epidemic Diarrhea Virus Spike Protein in the Prefusion Conformation. Journal of Virology, 2019, 93, .	1.5	59
69	A high-throughput inhibition assay to study MERS-CoV antibody interactions using image cytometry. Journal of Virological Methods, 2019, 265, 77-83.	1.0	12
70	Iterative screen optimization maximizes the efficiency of macromolecular crystallization. Acta Crystallographica Section F, Structural Biology Communications, 2019, 75, 123-131.	0.4	8
71	Crystal Structure and Immunogenicity of the DS-Cav1-Stabilized Fusion Glycoprotein From Respiratory Syncytial Virus Subtype B. Pathogens and Immunity, 2019, 4, 294.	1.4	26
72	Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape. Journal of Virology, 2018, 92, .	1.5	155

#	Article	IF	Citations
73	Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that Lack Somatic Hypermutation. Immunity, 2018, 48, 339-349.e5.	6.6	126
74	Chimeric <i>Pneumoviridae</i> fusion proteins as immunogens to induce crossâ€neutralizing antibody responses. EMBO Molecular Medicine, 2018, 10, 175-187.	3.3	10
75	Global site-specific analysis of glycoprotein N-glycan processing. Nature Protocols, 2018, 13, 1196-1212.	5.5	71
76	Clinical Potential of Prefusion RSV F-specific Antibodies. Trends in Microbiology, 2018, 26, 209-219.	3.5	42
77	Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis. Scientific Reports, 2018, 8, 15701.	1.6	408
78	Five Residues in the Apical Loop of the Respiratory Syncytial Virus Fusion Protein F ₂ Subunit Are Critical for Its Fusion Activity. Journal of Virology, 2018, 92, .	1.5	9
79	Structural basis for recognition of the central conserved region of RSV G by neutralizing human antibodies. PLoS Pathogens, 2018, 14, e1006935.	2.1	50
80	The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infectious Diseases, The, 2018, 18, e295-e311.	4.6	355
81	Neutralization of Diverse Human Cytomegalovirus Strains Conferred by Antibodies Targeting Viral gH/gL/pUL128-131 Pentameric Complex. Journal of Virology, 2017, 91, .	1.5	60
82	Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state. Nature Communications, 2017, 8, 14158.	5.8	58
83	A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Science Translational Medicine, 2017, 9, .	5.8	189
84	Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater <i>In Vivo</i> Protection than the Murine Precursor of Palivizumab. Journal of Virology, 2017, 91, .	1.5	24
85	Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate. Journal of Virology, 2017, 91, .	1.5	30
86	Crystal Structures of Two Immune Complexes Identify Determinants for Viral Infectivity and Type-Specific Neutralization of Human Papillomavirus. MBio, 2017, 8, .	1.8	20
87	Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor. Nature Communications, 2017, 8, 167.	5.8	58
88	Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E7348-E7357.	3.3	944
89	Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein. Nature Communications, 2017, 8, 1877.	5.8	53
90	Structure and immunogenicity of pre-fusion-stabilized human metapneumovirus F glycoprotein. Nature Communications, 2017, 8, 1528.	5.8	86

#	Article	IF	Citations
91	Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development. Vaccine, 2017, 35, 461-468.	1.7	53
92	RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 411-420.	1.7	28
93	Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors. Science Immunology, 2016, 1, .	5.6	180
94	Pre-fusion structure of a human coronavirus spike protein. Nature, 2016, 531, 118-121.	13.7	623
95	Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector. Journal of Virology, 2016, 90, 10022-10038.	1.5	31
96	Molecular mechanism of respiratory syncytial virus fusion inhibitors. Nature Chemical Biology, 2016, 12, 87-93.	3.9	121
97	Structural and molecular basis for Ebola virus neutralization by protective human antibodies. Science, 2016, 351, 1343-1346.	6.0	176
98	Engineering, Structure and Immunogenicity of the Human Metapneumovirus F Protein in the Postfusion Conformation. PLoS Pathogens, 2016, 12, e1005859.	2.1	50
99	A Cysteine Zipper Stabilizes a Pre-Fusion F Glycoprotein Vaccine for Respiratory Syncytial Virus. PLoS ONE, 2015, 10, e0128779.	1.1	38
100	Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein. PLoS Pathogens, 2015, 11, e1005035.	2.1	106
101	Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate. Journal of Virology, 2015, 89, 9499-9510.	1.5	58
102	Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein. Current Opinion in Virology, 2015, 11, 70-75.	2.6	96
103	A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nature Communications, 2015, 6, 8143.	5.8	248
104	Prefusion Fâ€"specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Science Translational Medicine, 2015, 7, 309ra162.	5.8	312
105	Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody. Science, 2013, 340, 1113-1117.	6.0	656
106	Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus. Science, 2013, 342, 592-598.	6.0	797
107	Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2. Immunity, 2013, 38, 176-186.	6.6	374
108	Structure and Function of Respiratory Syncytial Virus Surface Glycoproteins. Current Topics in Microbiology and Immunology, 2013, 372, 83-104.	0.7	205

#	Article	IF	Citations
109	Design and Characterization of Epitope-Scaffold Immunogens That Present the Motavizumab Epitope from Respiratory Syncytial Virus. Journal of Molecular Biology, 2011, 409, 853-866.	2.0	100
110	Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature, 2011, 480, 336-343.	13.7	794
111	Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing Epitopes. Journal of Virology, 2011, 85, 7788-7796.	1.5	327
112	Structural basis of respiratory syncytial virus neutralization by motavizumab. Nature Structural and Molecular Biology, 2010, 17, 248-250.	3.6	156
113	Structure of a Major Antigenic Site on the Respiratory Syncytial Virus Fusion Glycoprotein in Complex with Neutralizing Antibody 101F. Journal of Virology, 2010, 84, 12236-12244.	1.5	105
114	Structural Basis of Neutralization by Human Antibodies Targeting Crimean-Congo Hemorrhagic Fever Virus Glycoprotein Gc. SSRN Electronic Journal, 0, , .	0.4	0